Other Species / Isoforms
  CDC42EP4 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K5-ub
___MPILkQLVSSsV
0 2
CDC42EP4 (human) ___MPILkQLVSSsV K5-ub
CDC42EP4 (mouse) ___MPILKQLVSSsV K5
CDC42EP4 (rat) ___MPILKQLVSGsV K5
K5-m1
___MPILkQLVSSsV
0 3
CDC42EP4 (human) ___MPILkQLVSSsV K5-m1
CDC42EP4 (mouse) ___MPILKQLVSSsV K5
CDC42EP4 (rat) ___MPILKQLVSGsV K5
S11-p
LkQLVSSsVHskRRs
Upstream
0 4
Treatment
  • EGF
CDC42EP4 (human) LkQLVSSsVHskRRs S11-p
CDC42EP4 (mouse) LKQLVSSsVNSkRRs S11-p
CDC42EP4 (rat) LKQLVSGsVNskRRS S11-p
S14-p
LVSSsVHskRRsRAD
0 2
CDC42EP4 (human) LVSSsVHskRRsRAD S14-p
CDC42EP4 (mouse) LVSSsVNSkRRsRAD S14
CDC42EP4 (rat) LVSGsVNskRRSRAD S14-p
K15-ub
VSSsVHskRRsRADL
0 6
CDC42EP4 (human) VSSsVHskRRsRADL K15-ub
CDC42EP4 (mouse) VSSsVNSkRRsRADL K15-ub
CDC42EP4 (rat) VSGsVNskRRSRADL K15-ub
S18-p
sVHskRRsRADLtAE
Upstream
Downstream
1 11
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • cell motility, induced
  • cytoskeletal reorganization
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • DAG-lactone
CDC42EP4 (human) sVHskRRsRADLtAE S18-p
CDC42EP4 (mouse) sVNSkRRsRADLtAE S18-p
CDC42EP4 (rat) sVNskRRSRADLTAE S18
T23-p
RRsRADLtAEMISAP
0 3
CDC42EP4 (human) RRsRADLtAEMISAP T23-p
CDC42EP4 (mouse) RRsRADLtAEMISAP T23-p
CDC42EP4 (rat) RRSRADLTAEMISAP T23
R42-m1
RHTMHVGrAGDAFGD
0 1
CDC42EP4 (human) RHTMHVGrAGDAFGD R42-m1
CDC42EP4 (mouse) RHTMHVGRAGDAFGD R42
CDC42EP4 (rat) RHTMHVGRGGDAFGD R42
T50-p
AGDAFGDtsFLNSkA
0 1
CDC42EP4 (human) AGDAFGDtsFLNSkA T50-p
CDC42EP4 (mouse) AGDAFGDTSFLTSkA T50
CDC42EP4 (rat) GGDAFGDTSFLTSKT T50
S51-p
GDAFGDtsFLNSkAG
Upstream
0 1
Treatment
  • BI2536
CDC42EP4 (human) GDAFGDtsFLNSkAG S51-p
CDC42EP4 (mouse) GDAFGDTSFLTSkAR S51
CDC42EP4 (rat) GDAFGDTSFLTSKTG S51
K56-ub
DtsFLNSkAGEPDGE
0 2
CDC42EP4 (human) DtsFLNSkAGEPDGE K56-ub
CDC42EP4 (mouse) DTSFLTSkAREADDE K56-ub
CDC42EP4 (rat) DTSFLTSKTGEPDGE K56
S64-p
AGEPDGEsLDEQPsS
Upstream
0 44
Regulatory protein:
  • TBK1 (human)
Treatment
  • ischemia
CDC42EP4 (human) AGEPDGEsLDEQPsS S64-p
CDC42EP4 (mouse) AREADDEsLDEQASA S64-p
CDC42EP4 (rat) TGEPDGEsLDEQATS S64-p
S70-p
EsLDEQPsSsSskRs
0 1
CDC42EP4 (human) EsLDEQPsSsSskRs S70-p
CDC42EP4 (mouse) gap -
CDC42EP4 (rat) gap -
S72-p
LDEQPsSsSskRsLL
0 1
CDC42EP4 (human) LDEQPsSsSskRsLL S72-p
CDC42EP4 (mouse) EsLDEQASASKLsLL S70
CDC42EP4 (rat) EsLDEQATSSKLSLL T70
S74-p
EQPsSsSskRsLLsR
0 1
CDC42EP4 (human) EQPsSsSskRsLLsR S74-p
CDC42EP4 (mouse) LDEQASASKLsLLSR S72
CDC42EP4 (rat) LDEQATSSKLSLLSR S72
K75-ub
QPsSsSskRsLLsRK
0 2
CDC42EP4 (human) QPsSsSskRsLLsRK K75-ub
CDC42EP4 (mouse) DEQASASKLsLLSRK K73
CDC42EP4 (rat) DEQATSSKLSLLSRK K73
S77-p
sSsSskRsLLsRKFR
0 3
CDC42EP4 (human) sSsSskRsLLsRKFR S77-p
CDC42EP4 (mouse) QASASKLsLLSRKFR S75-p
CDC42EP4 (rat) QATSSKLSLLSRKFR S75
S80-p
SskRsLLsRKFRGSK
Upstream
Downstream
1 2
Effects on Modified Protein
  • molecular association, regulation
Effects on Biological Processes:
  • cell motility, induced
  • cytoskeletal reorganization
Kinase, in vitro:
  • PKCA (human)
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • DAG-lactone
CDC42EP4 (human) SskRsLLsRKFRGSK S80-p
CDC42EP4 (mouse) ASKLsLLSRKFRGSK S78
CDC42EP4 (rat) SSKLSLLSRKFRGSK S78
S89-p
KFRGSKRsQsVTRGE
0 1
CDC42EP4 (human) KFRGSKRsQsVTRGE S89-p
CDC42EP4 (mouse) KFRGSKRSQsVTRGD S87
CDC42EP4 (rat) KFRGSKRSQSVTRGD S87
S91-p
RGSKRsQsVTRGERE
0 2
CDC42EP4 (human) RGSKRsQsVTRGERE S91-p
CDC42EP4 (mouse) RGSKRSQsVTRGDRE S89-p
CDC42EP4 (rat) RGSKRSQSVTRGDRE S89
S105-p
EQRDMLGsLRDsALF
Upstream
0 15
Treatment
  • ischemia
CDC42EP4 (human) EQRDMLGsLRDsALF S105-p
CDC42EP4 (mouse) EQRDMLGsLRDsALF S103-p
CDC42EP4 (rat) EQRDMLGsLRDSSLF S103-p
S109-p
MLGsLRDsALFVkNA
0 21
CDC42EP4 (human) MLGsLRDsALFVkNA S109-p
CDC42EP4 (mouse) MLGsLRDsALFVkNA S107-p
CDC42EP4 (rat) MLGsLRDSSLFVKNA S107
K114-ub
RDsALFVkNAMsLPQ
0 4
CDC42EP4 (human) RDsALFVkNAMsLPQ K114-ub
CDC42EP4 (mouse) RDsALFVkNAMsLPQ K112-ub
CDC42EP4 (rat) RDSSLFVKNAMSLPQ K112
S118-p
LFVkNAMsLPQLNEk
0 35
CDC42EP4 (human) LFVkNAMsLPQLNEk S118-p
CDC42EP4 (mouse) LFVkNAMsLPQLNEk S116-p
CDC42EP4 (rat) LFVKNAMSLPQLNEK S116
K125-ub
sLPQLNEkEAAEKGT
0 3
CDC42EP4 (human) sLPQLNEkEAAEKGT K125-ub
CDC42EP4 (mouse) sLPQLNEkEAAEKDS K123-ub
CDC42EP4 (rat) SLPQLNEKEATEKDS K123
S138-p
GTSKLPKsLsssPVK
Upstream
0 24
Treatment
  • nocodazole
CDC42EP4 (human) GTSKLPKsLsssPVK S138-p
CDC42EP4 (mouse) DSSKLPKsLsssPVK S136-p
CDC42EP4 (rat) DSSKLPKSLSSsPVK S136
S140-p
SKLPKsLsssPVKkA
Upstream
0 13
Treatment
  • ischemia
  • nocodazole
CDC42EP4 (human) SKLPKsLsssPVKkA S140-p
CDC42EP4 (mouse) SKLPKsLsssPVKKA S138-p
CDC42EP4 (rat) SKLPKSLSSsPVKKA S138
S141-p
KLPKsLsssPVKkAN
0 6
CDC42EP4 (human) KLPKsLsssPVKkAN S141-p
CDC42EP4 (mouse) KLPKsLsssPVKKAD S139-p
CDC42EP4 (rat) KLPKSLSSsPVKKAD S139
S142-p
LPKsLsssPVKkAND
Upstream
0 32
Treatment
  • nocodazole
CDC42EP4 (human) LPKsLsssPVKkAND S142-p
CDC42EP4 (mouse) LPKsLsssPVKKADA S140-p
CDC42EP4 (rat) LPKSLSSsPVKKADT S140-p
K146-ub
LsssPVKkANDGEGG
0 1
CDC42EP4 (human) LsssPVKkANDGEGG K146-ub
CDC42EP4 (mouse) LsssPVKKADARDGG K144
CDC42EP4 (rat) LSSsPVKKADTRDGS K144
E156
DGEGGDEEAGTEEAV
0 7
CDC42EP4 (human) DGEGGDEEAGTEEAV E156
CDC42EP4 (mouse) ARDGGPKsPHRNGAt S154-p
CDC42EP4 (rat) TRDGSPKSPHRNGAT S154
A170
VPRRNGAAGPHsPDP
0 2
CDC42EP4 (human) VPRRNGAAGPHsPDP A170
CDC42EP4 (mouse) sPHRNGAtGPHSPDP T161-p
CDC42EP4 (rat) SPHRNGATGPHSPDP T161
S174-p
NGAAGPHsPDPLLDE
Upstream
0 31
Regulatory protein:
  • TBK1 (human)
Treatment
  • EGF
  • ischemia
  • LPA
  • nocodazole
  • SB202190
CDC42EP4 (human) NGAAGPHsPDPLLDE S174-p
CDC42EP4 (mouse) NGAtGPHSPDPLLDE S165
CDC42EP4 (rat) NGATGPHSPDPLLDE S165
T188-p
EQAFGDLtDLPVVPK
0 4
CDC42EP4 (human) EQAFGDLtDLPVVPK T188-p
CDC42EP4 (mouse) EQAFGDLMDLPIMPK M179
CDC42EP4 (rat) EQAFGDLMDLPVMPK M179
P232
MDKEEWDPEEGEGGY
0 12
CDC42EP4 (human) MDKEEWDPEEGEGGY P232
CDC42EP4 (mouse) MDKDQWGsEEEEEAG S223-p
CDC42EP4 (rat) MDKDQWGsEEEGEEE S223-p
Y255-p
TITQAPPyAVAAPPL
Upstream
0 2
Treatment
  • Su11274
CDC42EP4 (human) TITQAPPyAVAAPPL Y255-p
CDC42EP4 (mouse) SIVQAPPVLEVVPPL V247
CDC42EP4 (rat) GIVQGPPMLEAsPRG M249
A259
APPyAVAAPPLARQE
0 1
CDC42EP4 (human) APPyAVAAPPLARQE A259
CDC42EP4 (mouse) APPVLEVVPPLGRQE V251
CDC42EP4 (rat) GPPMLEAsPRGRQES S253-p
G267
PPLARQEGKAGPDLP
0 10
CDC42EP4 (human) PPLARQEGKAGPDLP G267
CDC42EP4 (mouse) PPLGRQEsKASWDQA S259-p
CDC42EP4 (rat) sPRGRQESKASWDHA S260
S292-p
GWAAAAPsPGsARsM
Upstream
0 26
Treatment
  • dasatinib
  • ischemia
  • metastatic potential
CDC42EP4 (human) GWAAAAPsPGsARsM S292-p
CDC42EP4 (mouse) GWAVVAPsPSSARSV S285-p
CDC42EP4 (rat) GWAAVAPSPSSARSV S286
S295-p
AAAPsPGsARsMGSH
Upstream
0 24
Treatment
  • dasatinib
  • nocodazole
CDC42EP4 (human) AAAPsPGsARsMGSH S295-p
CDC42EP4 (mouse) VVAPsPSSARSVGSH S288
CDC42EP4 (rat) AVAPSPSSARSVGSH S289
S298-p
PsPGsARsMGSHTTR
0 1
CDC42EP4 (human) PsPGsARsMGSHTTR S298-p
CDC42EP4 (mouse) PsPSSARSVGSHTTR S291
CDC42EP4 (rat) PSPSSARSVGSHTTR S292
S307
GSHTTRDSSSLSSCT
0 1
CDC42EP4 (human) GSHTTRDSSSLSSCT S307
CDC42EP4 (mouse) GSHTTRDsSsLSsYt S300-p
CDC42EP4 (rat) GSHTTRDSSSLSSYT S301
S309
HTTRDSSSLSSCTSG
0 1
CDC42EP4 (human) HTTRDSSSLSSCTSG S309
CDC42EP4 (mouse) HTTRDsSsLSsYtSG S302-p
CDC42EP4 (rat) HTTRDSSSLSSYTSG S303
S312
RDSSSLSSCTSGILE
0 1
CDC42EP4 (human) RDSSSLSSCTSGILE S312
CDC42EP4 (mouse) RDsSsLSsYtSGVLE S305-p
CDC42EP4 (rat) RDSSSLSSYTSGVLE S306
T314
SSSLSSCTSGILEER
0 2
CDC42EP4 (human) SSSLSSCTSGILEER T314
CDC42EP4 (mouse) sSsLSsYtSGVLEER T307-p
CDC42EP4 (rat) SSSLSSYTSGVLEER T308
S322-p
SGILEERsPAFRGPD
0 6
CDC42EP4 (human) SGILEERsPAFRGPD S322-p
CDC42EP4 (mouse) SGVLEERSPAFRGPD S315
CDC42EP4 (rat) SGVLEERSPAFRGPD S316
S344-p
RQPDKEFsFMDEEEE
Upstream
0 27
Treatment
  • ischemia
CDC42EP4 (human) RQPDKEFsFMDEEEE S344-p
CDC42EP4 (mouse) RQPDKEFCFMDEEEE C337
CDC42EP4 (rat) RQPDKEFsFMDEEEE S338-p